Parkinson's Disease: Clinical Signs and Symptoms,
Neural Mechanisms, Positron Emission Tomography,
and Therapeutic Interventions by Leenders, K. L. & Oertel, W. H.
NEURAL PLASTICITY VOLUME 8, NO. 1-2, 2001
Parkinson’s Disease: Clinical Signs and Symptoms,
Neural Mechanisms, Positron Emission T mography,
and Therapeutic Interventions
K.L. Leenders and W.H. Oertel
2
Groningen University Hospital, Department ofNeurology, Hanzeplein 1
PO Box 30. 001, 9700 RB Groningen, The Netherlands;
2Philipps-University Marburg, Klinikumfiir Neurologie, 35039 Marburg, Germany
SUMMARY
Parkinson’s disease is one of the most
frequent neurodegenerative brain diseases. Its
time course is slow and is characterized by
progressive loss of dopaminergic and other
brainstem neurons resulting in malfunctioning of
the cerebral neuronal systems responsible for
motor functions. The clinical signs are slowness
of movement, muscle rigidity and rest-tremor
amongst other features. The cause of the disease
is unknown, but recently involvement of genetic
factors is being researched. Positron emission
tomography (PET) allows in vivo determination
of striatai dopaminergic activity. This has
increased our insight in the pathophysiology of
the disease and permits direct study of disease
progression at a biochemical level and equally to
monitor whether potential neuroprotective inter-
ventions are indeed effective. Thus far no drug
has emerged but promising substances are
currently being studied.
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INTRODUCTION
Parkinson’s disease (PD) has for the first time
been described in a comprehensive way in 1817 by
James Parkinson in an article entitled "An Essay
on the Shaking Palsy". The disorder has since then
been named after him. The diagnosis PD is made
on clinical grounds solely since there does not
exist a specific laboratory test to confirm the
characteristic cerebral pathological alterations
which lie at the basis of this condition. In most
cases the clinical pattern of signs and symptoms is
sufficiently clear to make the diagnosis with
confidence. However, a certain number of patients
will pose considerable difficulties as to the correct
diagnosis, particularly in early stages of their
disease, even for an experienced neurologist.
Overlap with diseases which are not PD, but are
accompanied with some form of parkinsonistic
features, may occur regularly.
In PD at least two of the three cardinal signs
bradykinesia, rigidity and tremorneed to be
present (Levy & Cummings, 1999). The tremor is
typically prominent when the patient is at rest. In
addition, a large number of other signs and
symptoms may be present at different stages of the
disease and in individually varying composition or
intensity: impaired postural reflexes, masked face,
low speech volume, swallowing difficulty, micro
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graphia, flexed posture, small shuffling steps, move-
ment initiation problems, freezing. The clinical
picture often is further complicated by depression.
Certain neuropsychological functional impairments
and even a dementing condition may develop at
later stages. The onset of PD is insidious and
usually unilateral. Also with progression of the
disease, when both body sides are affected, the
asymmetries remain. Most commonly the disease
starts at middle age with increasing prevalence
above the age of 50 years, but ’young onset cases’
are not uncommon. Progression is in most cases
slow but inexorable. The endstage of the disease is
reached after many years, usually more than ten.
In this chapter, apart from clinical features,
some aspects of the pathophysiology of the disease
will be described. In particular the role of positron
emission tomography (PET) will be highlighted.
CAUSE
To date the cause of idiopathic Parkinson’s
disease is still unknown. Accelerated aging has
been discussed as a possibility, but is now
discarded mainly because the brainstem pathology
found in post-mortem PD tissue is clearly different
from the patterns of alteration seen with aging
(Hirsch et al., 2000). Genetic and environmental
factors have been investigated over the last decades
without, as yet, a clear-cut unifying unimodal
causative model. During the last few years,
possible genetic influences have become the focus
of attention. Only in a minority of cases PD occurs
in a familial context, although an overall increased
relative risk (compared to the population at large)
of two to three for family members ofPD patients
to become afflicted has been found. This is
comparable to the situation in Alzheimer’s disease.
Mutation ofthe alpha-synuclein gene (chromo-
some 4q21-23) has been identified in one large
Italian family and in five Greek families. That
mutation gave rise to an autosomal dominant
pattern of inheritance of parkinsonism. The
clinical expression of the disease, however, was
not quite typical for PD in the case of the
Ala53Thr point mutation of the chromosome. For
instance, the disease manifested itself at early
ages. The Ala30Pro point mutation, recently
discovered in a German family, however, resulted
in a syndrome which phenotypically was much
more like that seen in idiopathic sporadic PD
(Kruger et al., 2001).
Mutation of the Parkin gene (chromosome
6q25-27) has been identified as the cause of an
autosomal-recessive juvenile form of parkinsonism,
although the start of the disease at an early age and
other atypical neuropsychological features again
distinguish this condition somewhat from the
’common’ form of PD. In the meantime, a
spectrum of different alterations of the chromo-
some (various deletions or point mutations and
others) have been found in the reported families.
Thus, apparently a widely varying number of
genetic pathological changes of several chromo-
somes can ’give rise to parkinsonism (Klein et al.,
2000).
It neds to b ralizd, howwr, that in th
owrwhdming majority of familial ass of
Parkinson’s disease, or in sporadi PD patients for
that matter, no gneti abnormality has bn
identified. In th majority of ass, therefore, it is
blivd that nvironmental factors, possibly on
the basis of som form of gnti susceptibility,
play a major hitherto unknown rol. Som haw
suggested that th pla of birth and rsidn
sem to play a greater rol than the ra. Afro-
Americans living in th U.$. hav a narly fiw
tims higher risk as Africans living in Nigeria.
Afro-Americans and Caucasians living in th same
ommunity in th U.S. have similar risks of
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CLINICAL SIGNS AND SYMPTOMS
The patients usually notice rest tremor or
slowing of movements in one form or the other as
a first sign or symptom. Rigidity in the form of
stiffness and pain, on the other hand, is rarely
reported as the main complaint by the patient,
although it is a characteristic sign often to be
found at patient examination. Rigidity is determined
by passive movement by the examiner of the neck,
upper and lower limbs of the patient. Increased
muscle tone throughout the range of motion is
looked for. If the rigidity is mild, it may be
accentuated by letting the patient move the
contralateral limb by opening and closing the hand.
Rigidity should be distinguished from spasticity
because the increase in tone in that condition is
more prominent with the initiation of passive
movement and is greater in one direction than in
the other. Spasticity results from a lesion at the
level of the upper motor neuron and is accom-
panied by an increased stretch reflex and other
alterations. These latter findings are not seen in
patients with rigidity.
Postural instability is not a presenting symptom
or sign of PD but can certainly arise in the course
of the disease. This needs to be tested specifically
when the patient is examined in order to categorize
the patient in the widely used Hoehn and Yahr
scale: if the postural reflexes are affected, the
patient is assigned to category III instead of II of a
total five categories.
There are numerous other signs and symptoms
of PD that are often brought to the physician’s
attention by the patient or family members. Micro-
graphia is a common early sign, characterized by a
slowness or smallness to the handwriting. Mask
facies is another bradykinetic symptom characteristic
of Parkinson’s disease. Also, slowing of daily
living activities occurs, including such activities as
dressing, bathing, turning in bed, getting in and out
of a chair. Well-known are the problems with gait
in PD" some shuffling or dragging of a leg. The
posture is often stooped with flexion of the knees,
hips, trunk, and neck. Bradykinetic or hypophonic
speech, which may require the patient to repeat
himself frequently, is one of the bulbar symptoms.
Drooling is also common and choking may occur.
The loss of the sense of smell, or anosmia, in
relation to alterations of the dopaminergic pathway
projecting to the bulbus olfactorius, has been well-
documented in Parkinson’s disease. It is also
possible that patients will present with a foot
dystonia, in which the foot will turn in and with
involuntary curling of the toes, especially in the
morning. This may be an unpleasant symptom,
often accompanied by pain. If it occurs later in the
disease it usually signifies a relative understimu-
lation of the dopaminergic system due to low
blood drug levels, particularly early in the moming
when during the night no medication has been
taken.
Idiopathic PD needs to be differentiated from
other conditions causing parkinsonism (Levy &
Cummings, 1999). Certain drugs like neuroleptics
but also others may induce parkinsonism. Atypical
PD can occur in the context of other diseases like
Progressive Supranuclear Palsy (PSP) or multiple
system atrophy (MSA). If a supranuclear gaze
palsy, particularly a downgaze palsy, is present, a
PSP is more likely. In that condition, also frequent
falls early in the disease are characteristic in
addition to more axial (nuchal) rigidity compared
to limb rigidity. The signs are often symmetrical,
and a resting tremor is absent or only mild.
Response to parkinsonian drugs is commonly poor
or absent, although early on there may occasionally
be a good effectivity. An MSA is suspected if
involvement of the upper motor neuron or a
cerebellar syndrome is found. Often the autonomic
nervous system is affected too, resulting, for
example, in micturition problems or orthostatic
hypotension. Also MSA develops usually rather
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hypotension. Also MSA develops usually rather
rapidly, symmetrically, and without much of a
tremor and does not respond well on anti-
parkinsonian medication. Patients with early-onset
or rapidly progressive dementia, accompanied with
visual hallucinations not induced by medication,
are more likely to have diffuse Lewy body disease
or Alzheimer’s disease. Patients with an early
onset of urinary incontinence should be evaluated
for normal pressure hydrocephalus.
Even though a patient with parkinsonism can
usually be classified correctly during life, a
definitive diagnosis of PD can be made only by
autopsy (see below). Neuroimaging studies applying
radiotracers during life can reliably demonstrate
the presence of a presynaptic dopaminergic defect
in the nigrostriatal neuronal system, but as such,
this does not differentiate between the various
forms of parkinsonism. Usage of a combination of
various tracers, however, can help to clarify the
biochemical changes and thus assist in making a
diagnosis.
PATHOLOGY
A normal midbrain at post-mortem shows the
substantia nigra (Latin for ’black substance’) as
dark black/brown colored areas between the
cerebral peduncles and the nucleus ruber. This
abundant pigmentation is caused by the neuro-
melanin accumulation in the cell bodies of the
nigral dopaminergic neurons. In PD, the nigral
dopaminergic neurons are gradually and to a
certain extent lost, particularly in the lateral and
ventral parts of the substantia nigra. Therefore, the
midbrain of a PD patient looks bleak because of
depigmentation. Microscopically there is also
some gliosis in the substantia nigra in PD. Many
lesioned dopaminergic neurons contain abnormal
inclusion bodies, the Lewy body inclusions. These
are characterized by a dense pink center and a
lighter pink periphery. The combined loss of
dopaminergic neurons in the substantia nigra,
together with the inclusion ofLewy bodies, is seen
as the pathological hall-mark of idiopathic PD.
There are speculations about why in PD
usually only the lateral and ventral part of the
substantia nigra is affected. It has been found that
the glial cells in that particular part of the
substantia nigra have different biochemical
properties (Hirsch, 2000). Possibly in the case of
PD, protective properties of glial cells in those
regions of the substantia nigra are not operational
or not sufficiently effective.
Various biochemical deficits or cell biological
alterations in the brain tissue of PD patients have
been found: mitochondrial complex I is impaired
in the substantia nigra, iron accumulation is
increased, and signs of increased oxidative stress
and reduced defenses against this stress have been
found, also increased apoptosis has been reported.
It is generally supposed that all these cellular
phenomena are the expression of dysregulation
relatively far down the cascade of events active in
the impaired neurons in PD. The quest will be to
find the key step(s) which initiates all the above
mentioned pathological mechanisms.
BASAL GANGLIA CIRCUITS
The cerebral stations which plan and execute
movements are organized in a complex way.
Motor plans are stored, composed, and activated
by many parietal and frontal cortical regions. In
addition, two major systems interact with the
cortical action to make movements possible. The
cerebellum is necessary, for example, for obtaining
accuracy and context-shaping of movements. The
basal ganglia (mainly the striatum, pallidum,
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a role in learning automated skilled movements,
but their role is much more difficult to formulate
in physiological terms. They do seem to influence
temporal and spatial discrimination.
Within the cortex, the neurons have dense and
complicated cortico-cortical interconnections. In
contrast, the connections between the cortex and
striatum, between striatum and pallidum, between
pallidum and thalamus, and between thalamus and
cortex are all formed by single-layered elements.
This has been the basis for the efforts to determine
which synaptic transmission is excitatory or
inhibitory via the type of neurotransmitter at the
specific connections. Thus, a system of integrated
influence, either activating or inhibiting, could be
proposed for the basal ganglia system of cortico-
subcortico-cortical loops.
A central role in this system is played by the
dopaminergic nigrostriatal projection, which modifies
in various ways the transmission of the cortico-
striatal signals to the striato-pallidal projection
neurons. Since the dopaminergic neuronal system
is impaired in PD (see above), the basal ganglia
circuits are therefore in disarray (Bergman et al.,
1998). Ultimately this results in an altered firing
pattern of the internal part of the globus pallidus to
which the basal ganglia massively converge as
major output station. In particular, the functional
firing segregation between the pallidal neurons is
lost, leading to oscillatory activity of the pallidum
which is normally not present (Raz et al., 2001).
The pallidum has, in turn, an enormous divergent
connection with the cortex through the thalamus. It
therefore is understandable that the pathologically
altered firing pattern of the globus pallidus has a
deeply disturbing influence on the cortical functions.
The major projection of the basal ganglia is to the
supplementary cortex, which is an important motor
planning area: for example, initiation ofmovement
patterns, organization of sequential movements,
and other aspects are prepared there.
CLINICAL PHYSIOLOGICAL CONSEQUENCES
The clinical hallmarks of PDakinesia (unable
to start a movement), bradykinesia (slowness of
movement), and tremor---can thus be traced to the
arrangement of brain regions and their impaired
function. PD patients show a slow reaction time
and prolonged movement time. It appears that
velocity modulation during movements is affected
rather than an overall reduction of velocity.
Sequential movements ofPD patients are impaired,
and also simultaneous actions are difficult to
perform. An often observed phenomenon is that a
patient has to stop a certain movement in order to
be able to answer, when the patient is asked
something during the performance of a movement.
Apparent is the slowing of cognitive speed if
choice complexity increases. On the other hand, the
central processing of information is qualitatively
preserved, for example, use of advance information
for motor preparation.
18F-FLUORODOPA PET
Positron Emission Tomography (PET) is a
radiotracer method using special computer tomo-
graphic equipment to register the signals emerging
from the body after application of appropriate
radiotracers. The radiolabel is an isotope of
physiological atoms like carbon-11, oxygen-15 or
fluor-18, and these have certain characteristics:
they are short lived (minutes to hours) and emit
two high-energy gamma rays in opposite directions,
which enables regional quantitation of the signal at
high sensitivity. A further feature of these tracers
is that they usually are substances of a physio-
logical nature like derivatives of glucose, amino
acids, enzyme substrates, or receptor binding
substances. Taken together, the method allows in a
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activity in vivo of biochemical or physiological
processes in man or in experimental animals. This
can be done for the whole body, but here we limit
ourselves to the brain. Particularly for slowly
progressing degenerative brain diseases like PD,
such a method constitutes an important addition to
the possibilities of investigating patients with this
disease, since the brain is hardly accessible in a
direct way.
Relevant for the study of PD is the possibility
to use the tracer FDOPA (6-[F-18]-fluoro-L-dopa)
and PET. This tracer serves as a substrate for the
enzyme dopa-decarboxylase and is then accumulated
as fluorodopamine in the dopaminergic nerve
terminals. Particularly, the striatal capacity to
decarboxylase and store this tracer can be
performed quantitatively (Melega et al., 1991) In
PD patients, this conveys the degree of dopa-
minergic nigrostriatal neuronal impairment since
loss of nigral dopaminergic neurons will be
accompanied by a loss of striatal dopaminergic
nerve endings. However, also nigral dopaminergic
neurons which still are present but do not function
properly will most likely contribute to impaired
endogenous nerve terminal function. The parameter
to compare subjects can be a simple ratio between
the activity in the target striatal regions and a non-
dopaminergic brain reference region, for example,
occipital lobe or cerebellum.
Alternatively, a more complicated measure can
be derived from the dynamic time curves of
measured activity from the moment of application
of the radiotracer onwards. From these tracer-
kinetic models a specific constant can be calculated
reflecting specific regional tracer uptake. This
constant is generally named Ki. If the reference of
tracer input is the arterial plasma then the unit
should be written as Ki (plasma), but if the
reference is the occipital lobe the unit may be
denoted as Ki(occipital) or briefly Kocc. This unit
is expressed as per minute (1/min).
In PD the decrease in specific FDOPA uptake
is not uniformly distributed. The nigrostriatal
neuronal system of the most affected part in the
substantia nigra (lateral and ventral part) projects
mainly to the putamen. In the cross-sectional
images obtained via PET (see Fig. 1), it can be
seen that indeed the posterior parts of the striatum
show the largest decrease in FDOPA uptake while
the caudate nucleus regions are relatively spared.
In asymmetric PD patients the FDOPA uptake is
usually also asymmetrically impaired: the contra-
lateral side shows the highest decrease.
On average, in well established PD patients
the specific FDOPA uptake in putamen is about
40% to 45% of that in healthy age-matched controls
(Leenders et al., 1990).
START OF DOPAMINERGIC DECLINE
The decline of the striatal dopaminergic neuro-
modulation must have begun some time before the
clinical signs and symptoms appear. There has
been some speculation about how many years this
period in general might be. Post-mortem investiga-
tions suggest about 4 years. The progression data
obtained via FDOPA PET would support this
contention (Leenders, 1997). From Fig. 2 it can be
seen that indeed extrapolation from the estimated
period of clinical duration ofthe disease in a group
of patients towards the mean of healthy control
values there is an approximate time lag of 5 to 6
years before the striatal dopaminergic capacity to
accumulate FDOPA has decreased to a level when
the signs and symptoms appear. It can also be seen
that the striatal activity is not very low when the
disease manifests itself clinically. One interpret-
ation is, that the endogenous dopamine production
is very low indeed, at a stage when there still are a
sufficient number of nerve terminals left (although
malfunctioning) to take up exogenous levodopa or
FDOPA. It would explain why in the beginning of
the disease levodopa medication is so effective.PARKINSON’S DISEASE 105
Fig. I" Transaxial representation of cerebral FDOPA uptake in one healthy volunteer (left panel) and one PD patient
(right panel). The front ofthe brain is on the top ofthe image. Specific uptake oftracer (see text) is indicated
by a linear color scale, red being maximal uptake. The striatum on both sides ofthe brain is indicated by the
high intensity uptake of tracer in the healthy volunteer. It can be seen that in the PD patient the uptake into
striatum is diminished, particularly in the more posterior regions.
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Correlation between specific FDOPA uptake (expressed as Ki see text) in putamen and disease duration in
patients with PD. Values are compared to healthy age-matched control mean and two SD. Open circles are PD
patients and the open diamond is the mean ofthe controls.106 K.L. LEENDERS AND W.H. OERTEL
In the early stages of the disease, when there
are only a few signs and symptoms, there are
indications that the tracers which measure dopa-
mine reuptake sites (that is, the CIT-derived
substances, Benamer et al., 2000) either measured
with SPECT or with PET) are more reduced than
FDOPA. Later when the disease has been clearly
established, the two types of tracer indicate the
same degree of striatal dopaminergic impairment.
In our own data (to be published separately) it has
been shown that [I-123]-FP-CIT had a striatal
uptake of 40% compared with age-matched healthy
controls in de novo PD patients with a UPDRS-III
motor score of less than 20. On the other hand,
FDOPA uptake in a similar group of PD patients
was 82% of healthy control values. One interpreta-
tion could be that the dopamine re-uptake sites at
the nerve terminals in the striatum of PD patients
are downregulated in an early stage of the disease
due to the low endogenous dopamine production
and, in turn, low dopamine concentration in the
synaptic cleft. Since the nerve terminals may still
be present at that stage (see above), it is under-
standable that these different uptake measures are
found. It emphasizes that the investigator should
know well at which biochemical features he is
looking. If this finding is confirmed, then it would
mean that in very early stages ofPD, the dopamine
reuptake tracers might be more sensitive in detecting
pathology compared to FDOPA.
GENETIC INFLUENCE ON FDOPA UPTAKE
Various members of families in which gene
alterations have been found have been investigated
with FDOPA PET.
Alpha-Synuclein gene
Eleven subjects of a family were investigated
(Kruger et al., 2001). Five were carriers of a mutation
of the alpha-Synuclein gene (Ala30Pro point
mutation). Of these five subjects, three had PD and
two had subtle signs. The symptoms in these
patients started at ages 54 to 76. PET scans on two
of the symptomatic subjects, two brothers, and on
one of the ’non’ symptomatic subjects, a sister of
the two PD patients, were performed (Kruger et al,
2001). The two brothers (aged 65 and 57), off-
spring of non-consanguinent parents, presented as
patients with dopa-responsive PD. They were
found to have the mutant gene 4q21-q23 (alpha-
synuclein). The oldest brother (65) started with
micrographia at age 54. Gradually a more
pronounced general hypokinesia developed. Initial
levodopa therapy resulted in an improvement of
motor signs, but despite additional pharmaco-
therapy, he developed severe bradykinesia, more
pronounced on the left side, rigidity, and moderate
postural imbalance. Recently choreatic peak dose
dyskinesia, mainly axially, occurred. Up till now
tremor, autonomic failure, or a marked cognitive
impairment remained absent. The Unified
Parkinson’s Disease Rating Scale III (Motor
Examination Score) was 55 and his Hoehn & Yahr
Stage wis Ill-IV (while on medication). The
youngest brother (57) suffered from (mainly right
sided) hypokinesia and mild limb rigidity since 3
years. Combined pharmacotherapy (levodopa and
dopamine agonist) attenuated motor signs
successfully, and no other parkinsonian, cognitive,
or autonomic signs have occurred till now. The
Unified Parkinson’s Disease Rating Scale Ill
(Motor Examination Score) was 12 and his Hoehn
& Yahr Stage was II (while on medication). Their
sister (52), who also had been tested positive for
the mutant gene, had no history of parkinsonism
and was clinically unaffected. Their mother, who
suffered from parkinsonism, died at the age of 60.
No other family members are known to have
movement disorders or related diseases. The two
patients had a reduced FDOPA uptake in striatum
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whereas the sister had normal uptake values. In
these subjects, also FDG PET scans which
measure regional cerebral glucose consumption,
were performed. Several brain regions showed
energy consumption deficits in accordance with
some neuropsychological deficits. The other
brother and even the sister had some FDG uptake
impairments. This was also consistent with some
deficits apparent at neuropsychological testing.
In summary, the findings in this family
indicate that this particular genetic mutation leads
to a form of parkinsonism that is very much like
the common idiopathic form of PD. In will be of
interest to follow the unaffected sister in order to
detect in which sequence the clinical and cerebral
biochemical impairments will arise.
Parkin gene
Mutations in the Parkin gene (chromosome
6q25-27) yield an autosomal recessive form of
juvenile PD. Exons 3 to 7 are usually affected. A
particular characteristic is that no Lewy bodies
have been found at post-mortem examination. Two
brothers from an Israeli study were investigated
with FDOPA PET (Portman et al., 2001). Both
brothers were homogenous for large deletions of
exon 4, 5, and 6. They were first degree cousins.
The eldest started with clinical signs and
symptoms at age 35 and had his PET investigation
at age 55. The youngest brother started at age 28
and was PET investigated at age 49. Their clinical
stage was Hoehn & Yahr Stage IV to V (without
medication). FDOPA uptake in putamen was 13%
to 28% and in caudate nucleus 13% to 33% of
healthy control values. These findings are similar
to those reported earlier (Broussolle et al., 2000).
These authors described three non-related patients
who had the disease for a very long time and in
whom various deletions and mutations of the
Parkin gene were found. The FDOPA uptake in
putamen in these patients was between 28% and
44% ofnormal.
In summary, it can be said that the abnormalities
found with FDOPA PET are different from those
found in idiopathic PD: the decreases are more
severe and also the caudate nucleus is heavily
affected. This would bein concordance with the
clinical picture which usually is different from PD,
particularly concerning the early age of start.
However, a recent paper (Klein et al., 2000)
presented a family with Parkin gene mutations in
whom the affected family members were clinically
indistinguishable from idiopathic sporadic PD.
Twin studies
One study reported FDOPA results in 18
monozygotic and 16 dizygotic twin pairs, ofwhom
one had PD (Piccini et al., 1999). At baseline the
concordance for the FDOPA uptake (reduced in
the clinically not-affected twin) was significantly
higher in the monozygotic (55%) than in the
dizygotic twin pairs (18%). The asymptomatic
monozygotic cotwins all showed progressive loss
of dopaminergic function over seven years and
four developed clinical PD. None of the dizygotic
twin pairs became clinically concordant. These
findings support some role for genetic factors in
the causation of PD. However, the expression of
genetic susceptibility must be rather varying since
the latencies for clinical concordance vary greatly
and may last for many decades. Twin studies have
appealing characteristics but also a number of
pitfalls, for example, the heavy selection bias and
the particular biological situation of the subjects
involved. Another recent paper studying a large
cohort of twins (Tanner et al., 1999) again found
no genetic component to be evident when the
disease begins after age 50 years. However, genetic
factors appear to be important when the disease
begins at or before age 50 years.108 K.L. LEENDERS AND W.H. OERTEL
Disease progression
As PD progresses, specific FDOPA uptake
into putamen decreasesthis is a marker that the
dopamine-producing cells in the substantia nigra
projecting to the putamen are continuing to die
with relatively the highest rate of decline in the
first years ofthe disease (see Fig. 2).
In the literature, only a few reports are
available to assess properly the percentage decline
of specific striatal FDOPA uptake per year in an
average PD population. The percentages vary
between 1% and 18%, although most figures lie
between 5% and 10%. In healthy controls, the
decline is less than 1% per year. In view of the
slow decline of dopaminergic function in PD
patients and knowing that in the early phases ofthe
disease a large number of striatal nerve terminals
should still be present, albeit malfunctioning, there
is therefore a basis to propose neuroprotective
strategies if such strategies indeed are available.
Neuroprotection
Animal experiments have been positive in
administering one or other intervention to protect
cells from dying or assisting them in recovering
from damage. However, to date no such designs
have been convincingly successful in man.
Selegiline, a MAO (monoamine oxidase) inhi-
bitor has been extensively tested in, for example,
the DATATOP PD study. The basic idea was to
block MAO and thus diminish oxidative stress to
the dopaminergic system. Selegiline exerts neuro-
protection in various cellular and animal models
which are independent of MAO-B inhibition but
may be related to binding to glyceraldehyde-3-
phosphate dehydrogenase (Olanow et al., 1998).
No apparent benefit in terms of slowing of disease
progression in PD patients has been found.
In other studies, dopamine agonists have been
proposed to be protective, on the basis of these
drugs reducing glutamatergic drive on the substantia
nigra. An extensive 5-year study using ropinirol
and a 3-year study using pergolide comparing with
levodopa use have recently been concluded, and
the results will be published shortly. Both studies
were performed with clinical scales and longitudinal
FDOPA PET scans as outcome measures. In the
ropinirol study, 45 patients were included at
baseline. After five years, seven patients were still
on ropinirole monotherapy and showed a decline
of specific FDOPA putamen uptake of in total
12%, whereas the levodopa monotherapy patients
(n=4) showed a decline of 15% in 5 years. The 12
patients with ropinirole and levodopa as rescue
therapy showed a decline of in total 36%. The 3-
year pergolide study included 88 patients. The
pergolide monotherapy patients at 3 years showed
a putamen FDOPA decline of in total 8% and the
levodopa patients 14%. The difference was not
significant.
Thus, no clear-cut beneficial effect in terms of
protection against dopaminergic decline has been
found for either agonist. In fact, it can be said that
levodopa appears to be not deleterious in terms of
progression of the disease. Also a dopamine re-
uptake tracer measured with SPECT is used to
study the effects of pramipexol, another dopamine
D2 agonist used in everyday treatment of PD
patients. The preliminary data appear to be
comparable with those of pergolide and ropinirole
(personal communication).
Currently a glutamate antagonist, riluzole, is
being investigated in de novo PD patients in the
context of neuroprotection. Here also, FDOPA
PET scans are included in the evaluation of the
results. No results are available yet. The advantage
of riluzole as compared with deprenyl or dopamine
agonists is that the former has no direct clinical
symptomatic effect, whereas for the others a
combined effect was expected. To disentangle the
two effects in multicenter large scale longitudinal
studies will be difficult.PARKINSON’S DISEASE 109
Increased apoptosis has been suggested to be
present in the substantia nigra and may be
triggered by various mechanisms: oxidative stress,
mitochondrial dysfunction, excitotoxicity, excessive
concentration of iron (Jenner & Olanow, 1998).
All these unfavorable factors have been demonstrated
to be present in the substantia nigra. Selegiline has
been proposed (see above) to be a potential
candidate to exert neuroprotection since not only
does it inhibit MAO-B to reduce oxidative stress
but also has it been shown to exert neuroprotection
in various cellular and animal models which are
independent of MAO-B inhibition but possibly
related to binding to glyceraldehyde-3-phosphate
dehydrogenase. The activity of the latter enzyme is
taken to be an indicator for apoptosis activity. The
major problem of disentangling the neuroprotective
effect of a substance from its clinical effectiveness
is demonstrated also in the case of selegiline. The
situation is confounded by the metabolism of
selegiline: the desmethylated metabolite is supposed
to be protective, whereas the metabolites ampheta-
mine and metamphetamine were shown to be
antagonistic to this effect. As a consequence of
this TCH346 (formerly CGP 3466B), a propargyl-
amine related to selegiline, has been selected as a
more convenient candidate substance. TCH346 does
not lead to MAO-B inhibition, does not metabolite
into amphetamines, and is much more potent than
selegiline in inhibiting apoptosis. The application
of TCH346 in mice mutant for motoneuron
degeneration life span significantly increased, and
in an animal model of ischemia, survival of CA1
pyramidal neurons was shown (Andringa & Cools,
2000). Our own group was involved in testing
TCH346 in a group of 8 Rhesus monkeys (results
to be published). Sequential bilateral carotid artery
application of the dopaminergic neurotoxin MPTP
was used as primate Parkinson model. Four hours
after the second MPTP lesion, subcutaneous
TCH346 administration was started for two weeks
twice daily compared to vehicle. The four animals
receiving TCH346 did not show any reduction in
FDOPA uptake in the corresponding striatum,
whereas the vehicle treated animals did show the
expected significant decreases. The computerized
motor responses of the animals were in complete
agreement with the tracer findings.
Apoptosis inhibition is a new target to be tried
in humans since in experimental conditions,
effectivity against cell damage after toxins like
MPTP or after ischemia has been shown. The
question remains whether apoptosis is a key factor
in the progressive decline of the nigral dopamin-
ergic neurons or whether it is one of the stages in
the complex cascades of events once the lesion is
taking effect. Most likely it needs to elucidated
which factors right in the beginning of the process
are responsible for the impaired cell functions
before really effective protective or reparative
schemes can be tried with some outlook of success.
Restorative therapeutic designs like cerebral
implantation of viable possibly modified cells with
or without concurrent neurotrophic factors is an
option which in the end may certainly bear fruits.
Many encouraging experimental findings are
available. The recent cell biological work with
stem cells adds to the perspectives. However, the
level of knowledge and the practical applications
in this regard have to date not surpassed the
experimental level (Bjorklund & Svendsen, 2001;
Dunnett et al., 2000; Peschanski et al., 1999).
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